Compound library
Every profile uses the same structure: what it is, what humans have demonstrated, what is only preclinical, and what remains unknown.
Quaternary quinolinium small-molecule NNMT inhibitor
5-amino-1-methylquinolinium iodide
A small-molecule NNMT inhibitor with metabolic, liver, muscle, and cancer-model research in cells and mice, but no published human treatment trial.
Experimental synthetic pentadecapeptide
An experimental peptide with predominantly preclinical evidence, small uncontrolled human reports, and a recruiting Phase 2 trial without results.
Long-acting amylin analogue
An investigational once-weekly amylin analogue with published Phase 2 weight-management evidence and an active Phase 3 monotherapy program.
Fixed-dose amylin analogue / GLP-1 receptor agonist combination
An investigational cagrilintide–semaglutide combination with multiple completed, peer-reviewed Phase 3 trials.
GHRH-analog family with distinct DAC and non-DAC active moieties
A GHRH-analog family whose DAC, non-DAC, free-base, and salt identities should not be treated as interchangeable.
Informal two-component GH-axis combination label
A community label for CJC-1295 no DAC / Mod GRF(1-29) plus ipamorelin, with no verified direct combination study located.
Experimental sleep-associated nonapeptide
Emideltide
A sleep-associated nonapeptide with old, tiny, conflicting IV insomnia studies and no demonstrated subcutaneous effectiveness or safety record.
Synthetic pineal-derived tetrapeptide / AEDG peptide
Synthetic Ala-Glu-Asp-Gly tetrapeptide
A four-amino-acid peptide with limited human biomarker evidence and mostly cell, fly, and rodent research.
Copper(II)-binding tripeptide complex
A copper-binding tripeptide with mixed, formulation-specific topical human evidence and no established standalone injectable benefit.
Informal multi-compound blend label
A community label for a mixture described as GHK-Cu, BPC-157, and TB-500, with no direct combination study located.
Endogenous thiol tripeptide / cellular redox buffer
γ-L-glutamyl-L-cysteinylglycine
An endogenous redox molecule with good human biomarker evidence, mixed route-specific clinical results, and separate compounded-injection quality risks.
Placental glycoprotein hormone / LH-receptor agonist
Human chorionic gonadotropin
A placental hormone with approved fertility and endocrine uses, plus narrower off-label male hormone research.
Engineered low-IGFBP-affinity IGF-1 receptor agonist analogue
A modified IGF-1 research analogue with laboratory and animal evidence but no direct human treatment trial located.
Ghrelin-receptor agonist / growth-hormone secretagogue
A ghrelin-receptor agonist with limited intravenous human pharmacology and a negative Phase 2 postoperative efficacy study.
Reproductive neuropeptide / KISS1R agonist
KISS1-derived peptide
An upstream reproductive signal with Phase 2 IVF research and small controlled human hormone and sexual-processing studies.
Informal four-component blend label
A community label for a mixture described as GHK-Cu, BPC-157, TB-500, and KPV, with no direct combination study located.
Alpha-MSH-derived tripeptide
An alpha-MSH-derived tripeptide with preclinical inflammatory research and no human exposure identified by FDA.
GLP-1 receptor agonist
A once-daily GLP-1 receptor agonist with approved weight-management and diabetes products and a mature human evidence base.
Mitochondrial-derived signaling peptide
A mitochondrial-derived signaling peptide with an enrolling Phase 2a insulin-sensitivity trial and no posted efficacy results.
Synthetic alpha-MSH analogue and predominant MC1R agonist
Melanotan I
The common MT-1 name for afamelanotide, whose U.S. approval is limited to a specific clinician-placed implant for adults with erythropoietic protoporphyria.
Synthetic cyclic alpha-MSH analogue and nonselective melanocortin receptor agonist
Melanotan II
An experimental melanocortin agonist with very small human studies of pigmentation and erectile response, plus important regulatory and safety warnings.
Endogenous pyridine-dinucleotide coenzyme / redox cofactor
Oxidized nicotinamide adenine dinucleotide
A core cellular coenzyme with one disease-specific randomized trial and limited direct IV metabolism and tolerability evidence.
Synthetic neuroactive tripeptide / EDR peptide
Synthetic Glu-Asp-Arg tripeptide
A three-amino-acid peptide with limited human observations and mostly cell and animal neuroprotection research.
Nonselective melanocortin-receptor agonist cyclic heptapeptide
Bremelanotide
The melanocortin agonist approved as VYLEESI for one defined form of HSDD in certain premenopausal women.
Triple receptor agonist
An investigational triple agonist with Phase 3 human research in obesity, type 2 diabetes, and related complications.
Synthetic tuftsin-derived neuroactive heptapeptide
Thr-Lys-Pro-Arg-Pro-Gly-Pro
A tuftsin-derived heptapeptide with several small anxiety-comparator studies, one acute brain-imaging study, and broader animal and mechanistic research.
GLP-1 receptor agonist
A GLP-1 receptor agonist with several approved injections and tablets and a mature human evidence base.
Synthetic ACTH-fragment-derived heptapeptide
Met-Glu-His-Phe-Pro-Gly-Pro
A seven-amino-acid peptide with small and older human studies in brain-network imaging and stroke rehabilitation, plus substantially broader animal and laboratory research.
Mitochondrial cardiolipin-binding tetrapeptide
Elamipretide
The mitochondrial peptide also called elamipretide, with accelerated approval for one defined Barth-syndrome indication.
N-acetylated thymosin beta-4 heptapeptide fragment
A seven-amino-acid thymosin beta-4 fragment with no located human studies and a July 2026 nonbinding PCAC recommendation for 503A-list inclusion.
Growth hormone–releasing hormone (GHRH) analog
A GHRH analog approved for reducing excess abdominal fat in adults with HIV and lipodystrophy.
Synthetic 28-amino-acid thymic immunomodulatory peptide
A condition-specific immune-modulating peptide with real human trials, mixed results, and no demonstrated general-wellness benefit.
Endogenous 43-amino-acid actin-sequestering peptide
A full-length 43-amino-acid peptide with early, formulation-specific human studies that do not apply to TB-500.
GIP / GLP-1 dual receptor agonist
A dual GIP and GLP-1 receptor agonist with a large human evidence base.
Informal two-component combination label
A community name for BPC-157 plus TB-500, with no controlled study of the verified combination located.